Bicocca Open Archive

Logo unimib boa
CARBONE, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.154
AS - Asia 9.837
EU - Europa 9.158
SA - Sud America 1.529
AF - Africa 261
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 6
Totale 33.962
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.828
SG - Singapore 3.637
SE - Svezia 2.578
IT - Italia 1.892
CN - Cina 1.890
HK - Hong Kong 1.382
VN - Vietnam 1.342
RU - Federazione Russa 1.187
BR - Brasile 1.123
DE - Germania 1.032
IE - Irlanda 618
GB - Regno Unito 466
FR - Francia 333
IN - India 304
CA - Canada 190
BD - Bangladesh 172
KR - Corea 170
NL - Olanda 158
AR - Argentina 156
TR - Turchia 155
AT - Austria 150
UA - Ucraina 141
FI - Finlandia 132
IQ - Iraq 122
ID - Indonesia 115
CH - Svizzera 91
ES - Italia 82
JP - Giappone 82
PL - Polonia 82
ZA - Sudafrica 80
PK - Pakistan 78
MX - Messico 77
EC - Ecuador 67
PH - Filippine 63
DK - Danimarca 55
SA - Arabia Saudita 48
VE - Venezuela 47
CO - Colombia 44
MY - Malesia 43
UZ - Uzbekistan 34
MA - Marocco 33
EG - Egitto 26
BE - Belgio 24
JO - Giordania 24
CL - Cile 23
PY - Paraguay 23
DZ - Algeria 21
LT - Lituania 21
AZ - Azerbaigian 20
KE - Kenya 20
ET - Etiopia 18
IL - Israele 18
RO - Romania 18
PT - Portogallo 17
PE - Perù 15
TN - Tunisia 15
TW - Taiwan 15
BO - Bolivia 14
UY - Uruguay 14
AE - Emirati Arabi Uniti 13
JM - Giamaica 13
NP - Nepal 13
TH - Thailandia 13
AU - Australia 12
CR - Costa Rica 12
CZ - Repubblica Ceca 12
RS - Serbia 12
OM - Oman 11
PS - Palestinian Territory 11
AL - Albania 10
SN - Senegal 9
SY - Repubblica araba siriana 9
BG - Bulgaria 8
GR - Grecia 8
PA - Panama 8
KZ - Kazakistan 7
SK - Slovacchia (Repubblica Slovacca) 7
AO - Angola 6
DO - Repubblica Dominicana 6
IR - Iran 6
CI - Costa d'Avorio 5
HN - Honduras 5
HU - Ungheria 5
LA - Repubblica Popolare Democratica del Laos 5
MM - Myanmar 5
BY - Bielorussia 4
GE - Georgia 4
GH - Ghana 4
LB - Libano 4
MU - Mauritius 4
NZ - Nuova Zelanda 4
QA - Qatar 4
CG - Congo 3
GT - Guatemala 3
KG - Kirghizistan 3
KH - Cambogia 3
NO - Norvegia 3
SC - Seychelles 3
SV - El Salvador 3
TT - Trinidad e Tobago 3
Totale 33.908
Salva come PNG Salva come JPEG
Città #
Ann Arbor 2.274
Singapore 1.989
Stockholm 1.892
Hong Kong 1.334
Ashburn 998
San Jose 823
Frankfurt am Main 755
Fairfield 634
Dublin 597
Chandler 569
Milan 561
Woodbridge 486
Wilmington 477
Chicago 453
Ho Chi Minh City 410
New York 394
Houston 392
Santa Clara 348
Hanoi 323
Dallas 306
Los Angeles 306
Hefei 296
Seattle 264
Beijing 260
Dearborn 252
Cambridge 224
The Dalles 224
Princeton 215
Lauterbourg 159
London 152
Seoul 152
Jacksonville 148
Shanghai 139
Buffalo 131
Rome 126
Vienna 119
Nanjing 111
São Paulo 111
Council Bluffs 106
Moscow 105
Lawrence 103
Altamura 101
Zurich 82
San Diego 73
Munich 71
Toronto 70
Jakarta 67
Helsinki 65
Boardman 64
Orem 61
Tokyo 59
Warsaw 51
Haiphong 48
Baghdad 47
Florence 46
Nuremberg 46
Rio de Janeiro 44
Da Nang 42
Johannesburg 42
Monza 42
Turin 42
Denver 32
Guangzhou 32
Salt Lake City 32
Amsterdam 31
Biên Hòa 31
Paris 31
Phoenix 31
Chennai 30
Mumbai 30
Andover 29
Brooklyn 29
Lachine 29
Pune 28
Tashkent 28
Lissone 27
Nanchang 27
Poplar 27
Boston 26
Montreal 26
Tianjin 26
Bari 25
Atlanta 24
Columbus 24
Hải Dương 24
Guayaquil 23
Hangzhou 23
Istanbul 23
New Delhi 23
Quito 23
Elk Grove Village 22
Amman 21
Brussels 21
Can Tho 21
Changsha 21
Genoa 21
Ottawa 21
Buenos Aires 20
Dhaka 20
Fremont 20
Totale 21.883
Salva come PNG Salva come JPEG
Nome #
Prospective, randomised, placebo-controlled, phase 2 clinical trial assessing the efficacy and safety of oral vancomycin in patients with primary sclerosing cholangitis with/out inflammatory bowel disease in Italy: study protocol of VanC-IT trial 1.937
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score 568
The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis 457
A worldwide cross-ethnic study of quality of life in patients with PBC: Attitude or latitude? 423
Exploring the landscape of steatotic liver disease in the general US population 419
Quality of life in patients with primary biliary cholangitis: a cross-geographical comparison 398
Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid 379
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 374
Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study during the COVID-19 outbreak 356
Autoimmune liver disease, autoimmunity and liver transplantation 331
Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response 331
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 329
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 328
Risk stratification in primary sclerosing cholangitis 320
Accuracy of Liver Stiffness Measurement in assessing liver fibrosis in naïve patients with Primary Biliary Cholangitis 320
Endocrinology and Metabolic Diseases (Including Diabetes) 315
Liver Transplantation in Alcohol-Associated Hepatitis. Benefits and Limitations of Psychosocial Selection and Support in Alcohol Relapse. The Experience of a Tertiary Center in Italy 315
Calcineurin inhibitors and the IL12A locus influence risk of recurrent primary biliary cirrhosis after liver transplantation 314
Precision medicine in primary biliary cholangitis 314
FRI-008-Incidence, prevalence and mortality of primary sclerosing cholangitis in Italy: A population-based study 306
Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naïve patients with Primary Biliary Cholangitis: a dual cut-off approach 306
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 302
Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls 297
Autoimmune liver diseases 289
A NOVEL MACHINE-LEARNING, COMMON VARIANTS-BASED APPROACH TO PREDICT PRIMARY BILIARY CHOLANGITIS 289
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 285
FRI-006-Soluble CD163 and mannose receptor as markers of liver disease severity and long term prognosis in patients with primary biliary cholangitis 279
New Therapeutic Targets in Autoimmune Cholangiopathies 277
From pathogenesis to novel therapies in the treatment of primary biliary cholangitis 276
Additive beneficial effects of Fibrates combined with Obeticholic acid in the treatment of patients with Primary Biliary Cholangitis and inadequate response to second-line therapy: data from the Italian PBC Study Group 275
Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis 269
THU-010-Shedding light on the X chromosome contribution to the genetic architecture of primary biliary cholangitis 267
The mode of dexamethasone decoration influences avidin-nucleic-acid-nano-assembly organ biodistribution and in vivo drug persistence 265
Machine learning in primary biliary cholangitis: A novel approach for risk stratification 260
Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland 258
Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis 257
Immune system and cholangiocytes: A puzzling affair in primary biliary cholangitis 253
Ductular reaction, intermediate hepatocytes and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis 252
Artificial Intelligence and liver: Opportunities and barriers 245
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways 245
Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies 245
The challenges of primary biliary cholangitis: What is new and what needs to be done 245
Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach 243
Primary biliary cholangitis: a multifaceted pathogenesis with potential therapeutic targets 241
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid 237
Female preponderance of primary biliary cholangitis is all about our understanding of its autoimmune nature 231
Prognostic models in primary biliary cholangitis 230
Reply to: “A spotlight on natural killer cells in primary biliary cholangitis” 226
Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe 223
FRI-011-Ductular reaction, intermediate hepatocites and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis 222
Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055)) 222
Autoantibodies in patients with interleukin 12 receptor beta 1 deficiency 220
Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients 220
Artificial intelligence for precision medicine in autoimmune liver disease 218
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain? 218
Support of precision medicine through risk-stratification in autoimmune liver diseases - histology, scoring systems, and non-invasive markers 217
Deep learning helps discriminate between autoimmune hepatitis and primary biliary cholangitis 216
Improving predictive accuracy in primary biliary cholangitis: A new genetic risk score 216
Novel insights in primary biliary cholangitis (PBC) epidemiology using administrative records 216
A National Hospital‐Based Study of Hospitalized Patients With Primary Biliary Cholangitis 216
Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis 215
Real-world experience with obeticholic acid in patients with primary biliary cholangitis 214
Liver Transplantation for Primary Sclerosing Cholangitis (PSC) With or Without Inflammatory Bowel Disease (IBD)—A European Society of Organ Transplantation (ESOT) Consensus Statement 211
Comprehensive review of autoantibodies in patients with hyper-IgM syndrome 210
Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis 204
Role of ductular reaction and ductular–canalicular junctions in identifying severe primary biliary cholangitis 203
Genetics and epigenetics of primary biliary cirrhosis 201
Clinical and prognostic implications of acute onset of Autoimmune Hepatitis: An Italian multicentre study 201
The immunobiology of female predominance in primary biliary cholangitis 197
Primary sclerosing cholangitis: Burden of disease and mortality using data from the national rare diseases registry in Italy 197
Primary Sclerosing Cholangitis and Amyloid A Amyloidosis: Association or Coincidence? 196
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 195
Corrigendum to: “An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs” [J Hepatol 75 (2021) 572-581, (S0168827821003342), (10.1016/j.jhep.2021.04.055)] 195
Hepatitis C virus and nonliver solid organ transplantation 193
Non-invasive imaging biomarkers in chronic liver disease 189
Noninvasive identification of probable fibrotic nonalcoholic steatohepatitis across the spectrum of glucose tolerance in the United States 189
Leptin attenuates ischemia-reperfusion injury in the rat liver 189
Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma 188
Hepatitis C virus infection and diabetes: a complex bidirectional relationship 188
Geoepidemiology, Genetic and Environmental Risk Factors for PBC 186
Treatment discontinuation with peg-interferon: What to consider 183
How regenerative medicine and tissue engineering may complement the available armamentarium in gastroenterology? 182
Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study 182
The phenotypic landscape of primary biliary cholangitis and autoimmune hepatitis variants 181
Cell and organ bioengineering technology as applied to gastrointestinal diseases 181
Treatment of PBC-A step forward 181
An update on novel pharmacological agents for primary sclerosing cholangitis 180
Late acute liver allograft rejection; A study of its natural history and graft survival in the current era 177
Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis 176
Cost of illness of Primary Biliary Cholangitis - a population-based study 175
Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis 171
LLM-PBC: Logic Learning Machine-Based Explainable Rules Accurately Stratify the Genetic Risk of Primary Biliary Cholangitis 170
Primary Biliary Cholangitis: advances in management and treatment of the disease 169
The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort 167
Open challenges in the management of autoimmune hepatitis 166
Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history 166
Authors' reply to Zou et al 164
Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early-stage primary biliary cholangitis 164
The "gut microbiota" hypothesis in primary sclerosing cholangitis 163
European Society for Organ Transplantation (ESOT) Consensus Statement on Outcome Measures in Liver Transplantation According to Value-Based Health Care 162
Totale 26.223
Salva come PNG Salva come JPEG
Categoria #
all - tutte 113.443
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 113.443
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021616 0 0 0 0 0 0 0 0 0 213 207 196
2021/20221.871 193 187 214 143 141 142 54 105 79 145 170 298
2022/20232.934 333 740 266 252 264 370 126 130 222 76 83 72
2023/20242.687 71 111 108 258 293 580 383 76 156 173 93 385
2024/20256.364 445 717 389 347 506 216 322 290 669 813 685 965
2025/202614.905 1.534 958 1.171 1.569 1.502 792 2.095 867 1.300 3.117 0 0
Totale 34.838